Related Experiment Video
Updated: Jul 10, 2026
03:23
Three-Dimensional Cell Culture Models to Investigate the Epithelial Barrier in Eosinophilic Esophagitis
Published on: May 10, 2024
Hypereosinophilic syndromes.
1Division of Allergy/Outpatient Infectious Disease and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA.
Summary
Interferon-alpha (IFNalpha) is a key treatment for hypereosinophilic syndromes (HES), effectively controlling eosinophilia. Other options include bone marrow transplant for resistant cases and managing cardiovascular issues.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Hypereosinophilic syndromes (HES) are a group of disorders characterized by persistent eosinophilia.
- Current treatments for HES often involve cytotoxic agents, but new targeted therapies are emerging.
- Understanding the mechanisms of eosinophilopoiesis is crucial for developing effective HES treatments.
Purpose of the Study:
- To review the current understanding of HES treatment options.
- To highlight the role of interferon-alpha (IFNalpha) as a first-line agent for HES.
- To discuss management strategies for drug-resistant HES and its cardiovascular complications.
Main Methods:
- Review of existing literature on HES treatment.
- Analysis of the efficacy of interferon-alpha (IFNalpha) in managing eosinophilia.
- Discussion of advanced treatment modalities including bone marrow transplantation and surgical interventions for cardiovascular sequelae.
Main Results:
- Interferon-alpha (IFNalpha) is effective as a first-line agent for HES, with most patients responding to 2-9 MU/day.
- Dosage reduction of IFNalpha is possible after eosinophilia control; sudden discontinuation can lead to recurrence.
- Prednisone or hydroxycarbamide can be added for suboptimal responses; resistance may indicate underlying myeloproliferative or lymphoproliferative disorders or eosinophilic leukemia.
- Allogeneic bone marrow transplantation offers a new option for drug-resistant HES with reported durable responses.
- Cardiovascular complications of HES can be managed with cardiac surgery, but require concurrent control of eosinophilia to prevent recurrence.
Conclusions:
- Interferon-alpha (IFNalpha) is a valuable therapeutic agent for long-term control of hypereosinophilic syndromes (HES).
- Management of HES requires a multi-faceted approach, including targeted therapies, consideration of bone marrow transplantation for resistant cases, and management of cardiovascular sequelae.
- Further research is needed to clarify the role of anticoagulation in HES patients with cardiac thrombus or emboli.
Related Concept Videos
01:30Hypersensitivities
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
01:24Nephrotic Syndrome I : Introduction
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
01:22Lysosomal Hydrolases
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
01:30Allergic Reactions: Anaphylaxis
Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin, heparin),...
01:27Disorders of Erythrocytes
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
01:30Drug Toxicity: Allergic Reactions
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...